Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 242
- Registration Number
- NCT00263588
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Brighton, United Kingdom
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 829
- Registration Number
- NCT00262990
- Locations
- ๐บ๐ธ
The Arthur G. James Cancer Hospital, Columbus, Ohio, United States
๐บ๐ธOhio State University Medical Center, Columbus, Ohio, United States
๐บ๐ธMagee - Women's Hospital, Pittsburgh, Pennsylvania, United States
A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT00260156
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
- Conditions
- Interventions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 361
- Registration Number
- NCT00260208
- Locations
- ๐จ๐ญ
Novartis Investigational Site, Zurich, Switzerland
๐บ๐ธNovartis Investigative Site, East Hanover, New Jersey, United States
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2010-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT00258765
- Locations
- ๐ฆ๐บ
Novartis Investigative Site, Sydney, Australia
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT00251433
- Locations
- ๐ฎ๐ช
Novartis Investigative Site, Dublin, Ireland
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
- Conditions
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT00248157
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
- Conditions
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2012-04-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 260
- Registration Number
- NCT00248131
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4172
- Registration Number
- NCT00248170
- Locations
- ๐บ๐ธ
Chattanooga Oncology and Hematology Assoicates, PC, Chattanooga, Tennessee, United States
๐บ๐ธTexas Cancer Center ( Medical City Dallas Hospital), Dallas, Texas, United States
๐บ๐ธEl Paso Cancer Treatment Ctr-East, El Paso, Texas, United States
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT00247663
- Locations
- ๐ฏ๐ต
Novartis Investigative Site, Saitama, Japan